Endovasculaire 与破裂性动脉瘤手术治疗 PROTOCOL 试验更新。
The Endovasculaire vs Chirurgie dans les Anévrysmes Rompus PROTOCOL trial update.
机构信息
Vascular Surgery Unit, Hopital Henri Mondor, Paris XII, Creteil, France.
出版信息
J Vasc Surg. 2010 Jan;51(1):267-70. doi: 10.1016/j.jvs.2009.10.128.
Endovascular aortic repair (EVAR) treatment for ruptured aortoiliac aneurysms (rAIA) avoids the additional surgical insult to physiology that comes with laparotomy and open repair (OR). In systematic reviews, the pooled mortality rate from rAIA after EVAR is around 20% and morbidity around 40%. The proportion of patients with rAIA treated by EVAR is steadily increasing, as most centers are adopting an EVAR as a first line therapy. However, two trials, one randomized (n = 32) and one nonrandomized, failed to demonstrate any benefit of EVAR to OR. The multicentric randomized study named ECAR (for Endosvasculaire vs Chirurgie dans les Anévrysmes Rompus) was setup on 160 patients to compare the EVAR vs OR in rAIA. The primary outcome is mortality at 1 month. The study started in January 2008 and is still in progress.
血管内主动脉修复 (EVAR) 治疗破裂性腹主动脉瘤 (rAIA) 避免了剖腹手术和开放性修复 (OR) 带来的对生理的额外手术创伤。在系统评价中，rAIA 患者接受 EVAR 后的死亡率约为 20%，发病率约为 40%。接受 EVAR 治疗的 rAIA 患者比例稳步上升，因为大多数中心正在将 EVAR 作为一线治疗方法。然而，两项试验，一项随机（n = 32），一项非随机，未能证明 EVAR 对 OR 有任何益处。名为 ECAR（Endosvasculaire vs Chirurgie dans les Anévrysmes Rompus 的缩写）的多中心随机研究纳入了 160 名患者，旨在比较 rAIA 中 EVAR 与 OR 的疗效。主要结局是 1 个月时的死亡率。该研究于 2008 年 1 月开始，目前仍在进行中。
Zotero 插件